Guggenheim Starts Corbus Pharmaceuticals (CRBP) at Buy
Tweet
Share
E-mailGet Alerts CRBP Hot Sheet
Price: $10.38 +5.49%
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Guggenheim analyst Paul Jeng initiates coverage on Corbus Pharmaceuticals (NASDAQ: CRBP) with a Buy rating and a price target of $45.00.
For an analyst ratings summary and ratings history on Corbus Pharmaceuticals click here. For more ratings news on Corbus Pharmaceuticals click here.
Shares of Corbus Pharmaceuticals closed at $10.08 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Hinge Health signs $86M office lease in San Francisco
- Nuvectis Pharma (NVCT) files $200M mixed shelf
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Guggenheim, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
